Home / Transcripts / Arcutis Biotherapeutics, Inc. (ARQT) · May 6, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Earnings Call Transcript

May 6, 2026

NASDAQ US Health Care Biotechnology earnings 55 min

Earnings Call Speaker Segments

Brian Schoelkopf executive
#1

Thanks, Marvin. Hello, everyone, and I appreciate you being here this afternoon as we go over the business update and the financial results for our first quarter of 2026. You can find the slides for today's call in the Investors section on the Arcutis website. With me today are Frank Watanabe, our President and CEO; Todd Edwards, our Chief Commercial Officer; Patrick Burnett, our Chief Medical Officer; and Lasse Vairavan, our Chief Financial Officer. I want to remind all of you that forward-looking statements will be made during this call. Such statements carry certain risks and uncertainties, and what actually happens may be different, so we urge you to look over all of the company's filings with the Securities and Exchange Commission, which include descriptions of our business and risk factors; with that, I'll turn things over to Frank to get today's call started.

Todd Watanabe executive
#2

Thank you, Brian, and good afternoon to all of you. We're grateful, as we always are, that you've taken the time to be with us today. To kick off this call, I'd like to provide a look at what's recently been happening at Arcutis and how we're advancing along our grow, expand, build strategy. After that, Todd will give a commercial update, Patrick will cover R&D, and last, Latha will walk through the quarter's financials along with our thinking on 2026 investments aimed at driving ZORYVE inflection. So I'm beginning on Slide 5. By this point, I hope all of you are familiar with the grow, expand, build framework we've put in place to lay out our approach for sustaining near- and long-term growth for ZORYVE and for the company as a whole; put simply, we intend to keep growing the core ZORYVE business within our currently approved indications, to expand ZORYVE into further indications, and to build an innovative pipeline that reaches beyond ZORYVE. Beginning with the grow pillar, which is about driving momentum in our core approved indications, we're quite thrilled to have filed a supplemental NDA in April for ZORYVE cream, 0.05% in atopic dermatitis patients aged 3 to 24 months; these patients are substantially affected by AD and badly need safe and effective options, since only a very small number of therapies are approved today. Patrick will say more about the opportunity, but we view this as a major new opportunity for ZORYVE, and dermatology clinicians are highly enthusiastic about our data and the prospect of approval; in addition, we finished enrollment in a MUSE trial of ZORYVE foam, 0.3% for children aged 2 to 11 years with scalp and body psoriasis, and that study should support a submission for — to extend the label into this age group, matching the 0.3 cream; on the commercial side, we've successfully completed — we've essentially completed, pardon me, the expansion of our dermatology sales force so we can reach deeper into the dermatology landscape. And I'm glad to share that our expanded derm sales force has been in the field since this week, though naturally, any sales impact likely won't show up for a few months. We've also started building out our dedicated PCP and pediatric sales team, beginning with the recent hire of our Head of Primary Care franchise. This team will make a targeted effort to engage primary care and pediatric clinicians who already use a fair amount of topical therapies in their practices; we're also continuing to make meaningful progress on our expand pillar as we work to deliver ZORYVE's unique benefits to people dealing with chronic inflammatory skin conditions outside our currently approved indications who likewise need targeted innovative treatment solutions, with attention on diseases where ZORYVE has already shown compelling potential through case reports and case series. Also, to be precise, we are close to completing enrollment for our Phase II proof-of-concept study in vitiligo, plus we keep adding patients to our Phase II POC trial in hidradenitis suppurativa, or HS. Beyond vitiligo and HS, we are assessing further Phase II proof-of-concept trials in other indications, and of course we will let you all know about any additional choices we make. Then, lastly, we hit a significant milestone in our pipeline building work by starting a Phase Ia, Phase Ib trial for ARQ-234. The money we are putting in and the work we are doing to push our initiatives forward across these 3 pillars are establishing the foundation for additional ZORYVE sales inflection and operating leverage expansion in 2027 and well past that, along with putting us in position to maintain growth over the long term and, most importantly, broadening our impact on people living with chronic inflammatory dermatosis. Even though we now have a successful commercial franchise in ZORYVE, at our core we remain a biotechnology company that champions meaningful innovation within medical dermatology. These investments in innovation and growth show that intent. So with that, I will pass the call to Todd for a Q1 commercial update.

Todd Edwards executive
#3

Alright, thanks Frank, and good afternoon to everybody. Moving on to Slide 7. Once again we saw robust sales results during Q1, with net product revenues reaching $105.4 million, a 65% increase over the first quarter of 2025. This solid quarterly showing came about even though the usual Q1 seasonal effects on branded therapies were at play — things like patient deductible resets, higher co-pay usage, yearly insurance changes, and refills being pulled forward into Q4; that normal pattern got even more pronounced this year because of the severe weather events that hit various parts of the country during the quarter. As we had anticipated, when you put all of this together, the result was a sharper quarter-to-quarter decline in product revenues from Q4 into Q1 than the one we experienced in 2025, a year in which the seasonality pattern was muted because ZORYVE was first launched in atopic dermatitis. What matters most here is that the impact of this customary seasonality is now behind us, and we look ahead to demand growth resuming its strong quarter-over-quarter pace. Gross to net held steady, remaining in the 50s. And, as we said on the last call, we anticipate it will remain in that same range for the balance of 2026. Our Q1 gross to net rate came in better than Q1 2025 because of our evolving payer contracting, which helped product revenues during the period. Looking toward Q2, we expect quarter-over-quarter net sales growth, driven mainly by rising patient demand along with ongoing gross to net improvements as we move from where we are now toward the low 50s over the course of the year. Moving to Slide 8. Following the usual December-to-January dip in demand, weekly prescriptions on a rolling 4-week average, per IQVIA EXPONent data, have gone back to a healthy growth trajectory and hit roughly 21,000 prescriptions each week across all indications and formulations for ZORYVE. As this chart makes evident, ZORYVE keeps producing sustained Rx growth. Looking ahead across the remainder of 2026, our expectation is that rising demand will serve as the primary driver of revenue growth for ZORYVE. The most critical element underpinning this durable momentum remains the shift away from topical corticosteroids toward advanced targeted topical treatments, driven by evolving perspectives among health care providers and patients regarding the dangers associated with long-term topical steroid use; Patrick will address the developments we are observing in that area shortly. Demand growth during the latter portion of the year will receive an additional boost from the resources we have committed to expanding our dermatology sales force, while our efforts in primary care and pediatric settings should start producing results in the later stages of 2026 and into 2027. Let me add a bit more color on how demand looked for topical therapeutics and dermatology during Q1. I'm now on Slide 9. The chart there illustrates that for topicals, prescription volumes declined across every category in the first quarter of 2026 compared with the fourth quarter of 2025. Importantly, this pattern wasn't limited to branded products — it also appeared in topical corticosteroids, antifungals, vitamin D analogs, and topical calcleurin inhibitors. Because those categories are largely generic, they're generally less exposed to the seasonality that typically affects branded products during Q1. Even so, this year they posted notable quarter-on-quarter sequential decreases; in our view, that pattern reflects how the severe weather events during the first quarter hit dermatology prescription volume broadly, a headwind that stacked on top of normal seasonality and touched the whole topical segment. Notably, ZORYVE's prescription decline of 6% during the quarter was substantially smaller than that of the other branded non-steroidal topicals, which as a group fell 15% in the quarter. That relative outperformance offers additional proof of dermatology health care providers' and patients' rising preference for ZORYVE. Another driver of growth in the quarter was ZORYVE's comparative advantage, which helped us capture more of the market. Among prescriptions for branded topical treatments that aren't steroids, its portion climbed to 48% during Q1 — a gain of three percentage points versus where things stood when 2025 ended. Let's move to Slide 10. We're excited about the important investments we're funding in 2026, which should sustain ZORYVE's current trajectory and set up an acceleration in its growth during 2027 and afterward. The dermatology sales team build-out we told you about previously has wrapped up. Frank noted earlier in this call that we're glad to say the newly hired representatives started working in the field this week. Typically, it takes these reps about two months before they're comfortable with the accounts they cover. We think the extra sales reps we've added will start affecting demand once we get to Q3. On top of that, we're currently putting together our primary care and pediatric team, and we're happy to share that Katie Swoss has been brought on to lead this new franchise. Katie brings an extraordinary amount of both breadth and depth when it comes to commercializing dermatology therapeutics, and she's occupied a range of strategic and operational leadership roles. She's already begun assembling the remainder of her team. As we've explained previously, our approach with this sales force is extremely targeted, zeroing in on PCPs and pediatricians who are high-volume and early adopters, clustered in big metropolitan areas, which sets up this investment to be accretive right from the start. After that point, we'll assess bringing more people onto the sales force as we keep sharpening our approach and develop a deeper grasp of this area. Completing that first phase of expansion is something we expect to wrap up during the next quarter, followed by taking it into the field during Q3, with the earliest effect on demand showing up in the fourth quarter. To finish out our targeted commercial spending, the Free to Be Me campaign aimed directly at patients to build awareness, which stars Tori Spelling, Stella McDermott (her daughter), and Max Hona, a professional golfer, has produced robust and significant patient involvement. The experiences these individuals share together are assisting in generating awareness for ZORYVE across every indication and are connecting with a wide spectrum of patient groups. We're eager to see this key direct-to-consumer initiative keep moving forward, making sure we capture and mirror what patients say and go through as they live with and manage chronic inflammatory skin conditions, plus how ZORYVE affects their lives. So with that, I'll hand things over now to Patrick.

Patrick Burnett executive
#4

Thanks, Todd. Good afternoon, everybody. During Q1, we kept making substantial headway in what we're doing to help infants and young kids who deal with plaque psoriasis and atopic dermatitis. Let's begin with atopic dermatitis. Kids younger than 2 represent the most at-risk group within a population that badly requires new therapeutic choices beyond the few options available today. Speaking as a dermatologist, I can share from personal experience how hard it is to properly manage these conditions among these patients, because the approved therapies are so few, and how strongly moms, dads, and caregivers want treatments that work, are safe, and are well tolerated so their children can feel better. Having safe, well-tolerated options matters enormously for this age group, since both the immune system and the skin barrier remain in development; their plea is something we treat with deep seriousness, and we think ZORYVE's clinical profile and formulation match what this young patient population needs; during our March call, we pointed to the positive top line data from the INTEGUMENT infant Phase II trial of ZORYVE cream 0.05% in infants aged 3 to less than 24 months with mild to moderate atopic dermatitis. Building on what we discussed in March, we felt honored that our abstract was chosen for a prestigious late-breaker session, presented by Dr. Lawrence Eichenfield at the American Academy of Dermatology Annual Meeting at the end of March, and select portions appear here on Slide 12. More than 1/3 of study participants who finished 4 weeks of treatment reached a validated investigator global assessment for atopic dermatitis — a VIGA-AD success. That means a score of 0, or clear, or 1, or almost clear, alongside at least a 2-grade improvement. Nearly half of the infants reached a VIGA-AD score of clear or almost clear — a 0 or 1 — at week 4, and 24% got there by week 2. Turning to those infants who had at least mild scalp involvement at baseline, over 2/3 attained VIGA scalp success at week 4. And as noted before, 58.3% of infants saw at least a 75% reduction in their eczema area and severity index — an EASI-75 — at week 4, with 3/4 of infants reaching it by week 2. Now on the right, there's a representative patient. This 23-month old boy had prior treatment with topical corticosteroids and an IGA of 3, or moderate severity, at baseline, and by week 4 he shows significant improvement, with an IGA of 1, or almost clear. These photos, I believe, truly capture the meaningful impact our 0.05% cream provided to patients in this study, and why we're so excited that these data are already submitted to the FDA. Taken together, what we learned from the INTEGUMENT infant study provides meaningful clinical evidence regarding the potential of investigational ZORYVE cream 0.05% for infants aged 3 to 24 months, showing fast and strong efficacy across a number of clinical endpoints, along with very good tolerability and a favorable safety profile. Let's turn now to Slide 13. There's one especially noteworthy finding from INTEGUMENT infant that we presented at the AAD that I'd like to call out — specifically, how quickly ZORYVE reduced itch in these patients, based on caregiver reports. Among atopic dermatitis symptoms, itch is one of the most disruptive at any age, and how fast a treatment can bring itch relief matters greatly to a drug's therapeutic profile. Since the early stages of clinical development, we've understood that ZORYVE acts quickly on itch. On the left side of Slide 13, the chart displays itch improvement over time from our registrational INTEGUMENT-1 and 2 trials in atopic dermatitis, measured using WI-NRS, or worst itch numeric rating scale. As shown, itch reduction appeared as soon as 24 hours following the initial application, which was the earliest time point assessed in those trials. Still, based on our clinical trial experience and input from practicing clinicians, we recognized that ZORYVE's speed of impact on itch is exceptional; keeping that in mind, when designing the infant trial, we opted to assess itch impact through the dynamic pruritus score, or DPS, with measurements taken as early as 10 minutes after application. The chart on the right side of this slide presents the results of that analysis. Close to 50% of patients saw a 25% improvement in itch, according to caregiver assessment, within merely 10 minutes of applying ZORYVE, and 2/3 of patients obtained relief within 4 hours; beyond strengthening our confidence that ZORYVE will serve as an important therapeutic option for infant patients, this demonstrated speed of onset has also led us to study ZORYVE's effect on itch further. With that goal, we have recently launched a study called INTEGUMENT-Ich, designed to evaluate descriptive classification of pruritus over time with ZORYVE 0.15% cream in atopic dermatitis patients; enrollment in this 40-patient trial will start soon. We view the additional confirmation of ZORYVE's swift impact on itch that this trial aims to show — especially during the first 24 hours after starting therapy — as a key step toward better understanding and communicating ZORYVE's profile in atopic dermatitis. INTEGUMENT itch reflects our approach of generating further clinical data for our existing indications to strengthen the data set supporting ZORYVE — a key element of our growth strategy pillar. I'm eager to share future updates on other clinical activities we're advancing in that same direction. Now I'll give an update on our label expansion efforts aimed at supporting pediatric patient populations. To pick up on what Frank said at the start, back in April we filed a supplemental NDA with the FDA covering ZORYVE cream 0.05%, seeking to broaden its indication to include infants aged 3 to 24 months. We couldn't be more excited to have reached this important milestone, which could eventually deliver a new option that is safe, well tolerated, and effective for these patients. Worth highlighting is how quickly we managed it — only 3 months passed between reading out the top line data from our INTEGUMENT infant trial and getting the application submitted. That says a lot about how fast the Arcutis team is working for patients, and about how we've answered the sense of urgency expressed by the HCPs looking after these youngest AD patients. Now shifting to what we're doing to expand in pediatrics for plaque psoriasis. Enrollment has just wrapped up in our MUSE trial — the maximum MUSE trial — studying ZORYVE foam 0.3% in children aged 2 to 11 years old who have scalp and body psoriasis. That study is meant to underpin an sNDA filing that would extend the indication to this age group and bring the psoriasis indication for the 0.3% cream and foam into alignment. Should it win approval, ZORYVE foam might represent a genuinely distinctive therapeutic choice for caregivers assisting young children in managing a disease that, when it shows up in hair-bearing areas, has historically proven hard to treat. Also, as we noted earlier, the FDA is currently reviewing our supplemental NDA for ZORYVE cream 0.3% in psoriasis patients as young as 2 years, and the PDUFA action date of June 29 is coming up fast.

Patrick Burnett executive
#5

I want to point out that the reasoning behind broadening our label into the infant group for atopic dermatitis doesn't carry over to plaque psoriasis or seborrheic dermatitis. In atopic dermatitis, disease onset within these patient groups is frequent, whereas that's not the case for the other 2 conditions. With seborrheic dermatitis, the label we have today puts us in a position to serve the addressable patient population well, and if we potentially obtain a label expansion into the pediatric age range for plaque psoriasis, that would likewise leave us equipped to serve that addressable patient population. As the table on Slide 14 shows, these newest steps in widening our indications into additional pediatric and infant populations rest on a steady emphasis we've kept across the years on broadening ZORYVE's availability; what drives us is these younger children's need for effective, safe and well-tolerated therapeutic alternatives to topical corticosteroids; we also expect that once health care providers witness how well ZORYVE alleviates inflammatory skin disease in their most fragile and vulnerable patients, they'll lean more toward it and value the potential benefit ZORYVE could offer their adult and adolescent patients with the same diseases; now let's turn to Slide 15 and the pipeline. This is the build pillar of our strategy. We've now started the Phase I trial of ARQ-234, our novel biologic that targets CD200R, in healthy volunteers and adults with moderate to severe atopic dermatitis. A clear and distinct need exists for a systemic therapy among atopic dermatitis patients who have relapsed on IL-4, IL-13 drugs or who are refractory to them. Until recently, plenty of people in the drug industry and plenty of clinicians had hoped that agents targeting OX40 would fill that need. Yet following a series of disappointing clinical data sets and mounting safety concerns for these OX40-targeting programs, which have already led to discontinuations, that hope has faded, leaving a white space for novel new treatment pathways; we believe the CD200 axis that ARQ-234 targets could deliver an important new tool for providers and an important new option for patients. The CD200 axis holds a central role in both innate and adaptive immunity, with CD200 signaling lowering immune activation for T cells, type 2 innate lymphoid or ILC2 cells and myeloid cells and decreasing secretion of pro-inflammatory cytokines. Given the impact of this access, there's a solid basis for optimism about the role CD200R agonist programs may play in treating inflammatory diseases. The Phase I trial for ARQ-234 is made up of a single ascending dose or SAD component in healthy volunteers, which is currently ongoing, and a multiple ascending dose or MAD component followed by a proof-of-concept cohort, both in patients with moderate to severe atopic dermatitis. While we won't share the results from the trial until it's completed, we'll keep you apprised of our progress through these different components. Now moving on to Slide 16. As you can see, we've already delivered on several meaningful clinical milestones in 2026 and look forward to continuing clinical progress throughout the year. Also worth noting, enrollment is still ongoing for our Phase II proof-of-concept studies in vitiligo and hidradenitis suppurativa, or HS. Our vitiligo trial is close to completing enrollment, and we still expect to deliver a readout of trial results plus an update on our clinical development plan during Q4 of this year. Likewise, a comparable readout for our HS program in Q1 of 2027 remains on schedule. Todd mentioned earlier the ongoing move away from topical steroids toward advanced targeted topical therapies such as ZORYVE. As we've said on earlier calls, a steadily building consensus is emerging across the dermatology specialty regarding the clinical needs driving that shift, and we've seen additional evidence of it since the beginning of the year; on Slide 17, I point to just a handful of the recent discussions on this subject. I'd particularly draw your attention to one conclusion from the recently published expert consensus statement on advanced nonsteroidal topical therapies for atopic dermatitis, which appeared in March in the Journal of Drugs in Dermatology. As you can see, several of the most distinguished experts in the field concur that advanced nonsteroidal topicals ought to be favored over topical corticosteroids for long-term management of atopic dermatitis given their cleaner safety profiles; this reflects what we keep hearing from leaders in dermatology, and this expanding consensus will drive the conversion to the newer agents, among which ZORYVE is the leading treatment; with that, I'll hand the call to Latha to go into more detail on our Q1 financial results.

Latha Vairavan executive
#6

Thanks, Patrick. On Slide 19, net product revenues for the quarter came to $105.4 million — a 65% rise over Q1 of 2025. That year-over-year growth was mainly the result of higher patient demand. On top of that, gross to net was lower in the first quarter of 2026 than it was a year before, which also pushed net product revenues higher. As Todd said before, the main force behind this gross to net improvement was how our payer contracting has evolved. And even though our gross to net rate is lower at the start of the year, we still expect gross to net to sit in the 50s across 2026, finishing in the low 50s. Cost of sales for the first quarter totaled $9.8 million, versus $8.8 million in the first quarter of 2025, largely because ZORYVE sales volume has been growing; for the first quarter of 2026, R&D expenses came in at $30.6 million, against $17.5 million for the matching period in 2025. That year-over-year rise was mostly attributable to the $10 million milestone obligation owed to Ducentis shareholders, which was triggered when the first subject was dosed in the ARQ-234 Phase I trial during the quarter. SG&A expenses reached $74.1 million in the first quarter of 2026, compared with $64 million in the same period last year — a 16% increase — as we keep investing in commercialization efforts for ZORYVE. We expect a modest uptick in SG&A expense during the back half of the year, stemming from headcount-related costs tied to expanding the dermatology sales force and building out our primary care and pediatric sales team. Our revenue guidance stays at $480 million to $495 million for the full year 2026. Turning to Slide 20. As you can see, cash and marketable securities on our balance sheet stood at $224.3 million as of March 31, 2026. Notably, we stayed cash flow positive in the quarter, with $2.2 million of net cash provided by operating activities. We'll remain disciplined about the investments we make in the business so that positive cash flow continues through the remainder of the year. Total debt stands at $101.5 million, and we hold the right to draw another $50 million, in whole or in part, at our discretion through the middle of '26. I'm now on Slide 21. Given ZORYVE's continued broad adoption and the sustainable sales momentum the franchise has shown, we've hit a milestone that few biotechnology companies reach — positive cash flow at Arcutis. We first got to sustainable positive cash flow in the fourth quarter of last year, and we've communicated that through careful expense management, we expect to keep positive cash flows on a quarterly basis through all of 2026; this — the core ZORYVE business is strong, and the move from topical steroids to branded nonsteroidal topicals will keep presenting enormous growth opportunity for many years ahead. At the same time, we're putting money earned by our ZORYVE franchise to work again inside the company, so that growth bends upward in 2027 and afterward. Both of those elements are what fuel ZORYVE's expansion. Several such efforts were described to you on this call, among them adding sales representatives in derm and primary care, direct-to-consumer programs, spending on clinical work backing existing and possible future indications for ZORYVE, plus momentum across our novel pipeline. There are further efforts into which we are placing carefully managed capital, and we're eager to share specifics on those later in the year. For Arcutis, these outlays establish the groundwork for growth both soon and far out; they'll assist in further spurring ZORYVE's ongoing rise and in bending its path upward. ZORYVE is a franchise that turns a profit. And absent these high-impact, accretive outlays, we'd begin widening operating leverage during 2026. Looking toward 2027, we anticipate that the call for more spending on our present business will ease relative to this year. Combined with the expected ongoing sales climb for ZORYVE, we anticipate witnessing a substantial gain in our operating leverage and in cash flow generation across 2027 and afterward. Having said that, I'll hand the call back to Frank now for closing remarks.

Todd Watanabe executive
#7

Appreciate that, Latha, and once more, thank you all for being here with us today and for the ongoing interest you show in Arcutis. My gratitude to our team is enormous, and I take great pride in how hard they work, how devoted they are to creating value for shareholders, and how dedicated they remain to the patients we serve. So with that said, I'll turn the call over to Q&A.

Andrew Tsai analyst
#8

So it seems like gross to net did better than what we saw a year ago, in Q1 of last year. Could you perhaps give us a qualitative sense of what caused that improved percentage? Was any of it something you control? And what sort of favorable effect might that have for the remaining part of the year? I realize you sort of provided guidance on gross to net for the rest of the year. Would it be reasonable to think the blended gross to net for this year might come in better than the blended gross to net for 2025?

Todd Watanabe executive
#9

Sure. Yes. Todd, would you like to handle that one?

Todd Edwards executive
#10

Absolutely, Andrew — I'll address that. Thanks for asking. So, to confirm what was said earlier: when comparing this year's first quarter against Q1 2025, we did see an improvement in price. The main factor behind that year-over-year gain was better formulary positioning, as we moved to more preferred status rather than nonpreferred status with certain commercial plans. For a patient, that distinction means a smaller co-pay when the status is preferred instead of nonpreferred. When patients get preferred status and a reduced co-pay, the result is that Arcutis faces reduced co-pay costs and less co-pay buy-down, which is where our pricing benefit comes from. And although our rate sits below where it was a year ago, we still expect it to hold steady in the 50s for sure across the whole year. As was noted, we'll move down from the higher 50s at the start of the year toward the lower 50s by year's end, as patients keep buying down deductibles and our co-pay costs come down. Looking ahead, I'd say it's somewhat premature to predict how each of these dynamics will extend into later years. Even so, I have strong confidence that our gross to net will stay quite robust, and that we'll keep our gross to net inside the 50s moving forward. Thanks for the question.

Tyler Van Buren analyst
#11

To assist in putting a number on the sequential effect within the Q1 seasonality, when we look at it against Q4, could you walk us through what portion came from the gross to net impact as opposed to volume effects due to weather or pull forward in Q4? Then the second piece, or the follow-up, is this: I hear you saying Q2 sales are going to be higher than the first quarter, but do you think Q2 sales are likely to come in well above what was posted in Q4?

Todd Watanabe executive
#12

Tyler, alright, Todd, would you like to handle that one as well?

Todd Edwards executive
#13

Yes, certainly. Thanks, Tyler. Regarding how seasonality affected us from one quarter to the next, plus the gap between gross and net and demand, as we pointed out, we saw an improvement on gross to net thanks to the which that moved from nonpreferred into preferred, with the — as stated, demand coming in against that 6%. And when you consider seasonality, which is normal given that refills get pulled forward into Q4, we had employers whose insurance frequently shifts for employees effective January 1 of the year. Those transitions have an effect on ZORYVE, and then naturally the higher deductible reset plays a role too. And then, as we noted, the weather impact made this worse. I should also say that this entire weather effect and demand effect wasn't confined to the topical products alone. Looking at the systemics, they took a hit too. To illustrate, Otezla fell 11%, Rinvoq 3%, Dupixent 2%. That's on volume, caused by this seasonality and made stronger by the weather's effect. As for Q2 sales and how we view them moving ahead, I'll note that Q2 quarter-to-date through April 24 shows ZORYVE with 13% growth compared to Q1 across that same period. So we've begun Q2 very strongly here, and I'm quite confident we'll keep building on this demand trend and deliver robust quarter-over-quarter growth going forward.

Colleen Garvey analyst
#14

Colleen here, filling in for Seamus. As we consider the sales guidance for this year, what assumptions underlie the lower end of that range? Based on our calculations and the way prescriptions are currently trending, it's becoming hard for us to see how we land in the upper end of the guide, and consensus appears to already sit above it; so we're just trying to get a handle on what's pushing and pulling to keep the guide where it is.

Todd Watanabe executive
#15

Colleen, here's how I'd put it: we only refreshed the guidance back in February, which wasn't very long ago, and our intention isn't to revisit it each quarter, at least right now; so as the year moves along we'll keep assessing the trend, and should we conclude an update is warranted, we'll do one. That said, our view was that at this stage, with the year still young and Q1 being a bit unusual, holding steady seemed like the sensible call. Latha, Todd, I'm not sure whether either of you has anything further to add there.

Todd Edwards executive
#16

That's all, Frank.

Latha Vairavan executive
#17

To address that point, I'd put it this way — the guidance came out once the year had wrapped up; and like Frank mentioned, at this early stage of Q1 we don't feel any need to raise it. So as the year moves along, and once the guide rate shifts, you'll be in a better position to line up with where demand is trending. For the time being, though, I'd suggest you go with the top end and remain there.

Judah Frommer analyst
#18

We're grateful for the refreshed figures regarding overall scripts and the portion captured in that area. Is there anything you're seeing when it comes to NRx new scripts, along with any patterns that hint at how TRx might shift down the line?

Todd Watanabe executive
#19

Are you referring to share in terms of absolute volume?

Judah Frommer analyst
#20

Yeah.

Todd Watanabe executive
#21

What I'd say is... regarding the portion of new scripts, how that trend is going, whether anything has shifted, and has that formulary status perhaps had an effect on what those new scripts are doing? All right. Certainly. Todd, would you like to handle that?

Todd Edwards executive
#22

Sure, I'll handle that question. If we examine Q1 for ZORYVE and consider the new-to-brand prescriptions within the branded nonsteroidal topical category, looking at that overall group during Q1, ZORYVE accounted for 48% of the new-to-brand Rxs in the branded non-steroidal topicals space. That's something we find really encouraging. As a point of comparison, take Opzelura — that figure stood at 28%. What's more, regarding ZORYVE and the quarter-over-quarter decline in NBRx, we were essentially flat. That strikes me as yet another strong signal. Then there's our refills: if you look at total prescription volume, refills make up roughly 45% of it, which again is quite encouraging for us — not just on the NBRx side, but also because those refills are feeding into our TRx and our overall growth. And if I zoom into Q2, looking at roughly the past 3 to 4 weeks, we've seen really impressive NRx growth for ZORYVE, which is, once again, a terrific leading indicator of the TRx growth still ahead as we move through the quarter.

Uy Ear analyst
#23

If I could ask 2 things. First, could you help us get a handle on or put a number on what the infant atopic dermatitis conditions could bring in? Frank, I believe you called it a significant opportunity. And how — maybe just walk us through the way you'll go after that opportunity? Will it mostly come through the derm sales force you already have in place, or by building out the primary care pediatric sales force? That's my first one.

Todd Watanabe executive
#24

Go ahead. Did you have another one

Uy Ear analyst
#25

Yes, I do. For my second question, Lata, maybe this one's for you — SG&A came in below what I believe either we or the consensus had been looking for, by roughly $4 million. Given that your sales force expansion is now fully in place, should we anticipate a step-up during the second quarter? My impression was — assuming I caught it right, though I'm not sure where the baseline sits — that you were pointing to a modest rise in SG&A across the back half of the year. So perhaps you could just walk us through how spending will be paced over the course of the year.

Todd Watanabe executive
#26

Okay. Thanks. So Patrick, maybe that's where we begin, if you'd be willing to offer a dermatologist's view regarding the 3- to 24-month opportunity along with the unmet need. After that, Todd, perhaps you could speak to how we intend to reach that on the commercial side. And then Latha, if you would, could you take up his question regarding OpEx.

Patrick Burnett executive
#27

Okay, Frank. So regarding that group aged 3 to 24 months, I'll let another person speak to the sort of absolute magnitude of that population. But my view is they distinctly represent a set of patients where basically you've got crisaborol cleared in that setting plus perhaps 5 or 6 topical corticosteroids. So this genuinely is a population that, from our conversations out in the field with pediatric dermatologists — and keep in mind these patients aren't solely handled by pediatric dermatologists; a great many dermatologists, dermatology PAs and NPs also treat them — is one where folks truly battle to bring these patients under control. Clearly, you don't want to leap straight to a systemic in this population. They usually have greater body surface area involvement. Their condition often progresses rather fast as time passes into a fairly large percentage of skin affected; and as was hinted at earlier during the call, there's extremely strong sensitivity regarding corticosteroid exposure from the very start. I mean, these are incredibly young patients, and caregivers place developmental milestones right at the forefront of their concerns. So truly locating an option that aligns with that way of thinking — the ZORYVE profile, in my view, suits it perfectly; and I believe we hinted at how this represents a means of genuinely capturing the hearts and minds of prescribers, since if you can resolve this issue on their behalf, my sense is it substantially supports the brand's overall lift and what it signifies for the field. So that covers the derm angle. Now regarding how large the opportunity is overall, I think I'll hand things to you, Todd, to address that.

Todd Edwards executive
#28

Absolutely. Thanks, Patrick. And I want to stress again, like Patrick said, this group of patients is massively underserved. When you look at it, really the only options are EcrIA — which only works in that single use — plus topical steroids, and those obviously raise big worries for a caregiver when it comes to steroid exposure. Once we secure approval, the way we'll capture this opportunity going forward is through both the dermatology sales team and the PCP and pediatric sales team. The dermatology team, because we have pediatric dermatologists along with other dermatologists who see these patients, and we're communicating that there's a genuine value proposition here for this population. Then, naturally, with our primary care and pediatric group, they'll be reaching out to pediatricians to make sure they build that awareness for the patient. On top of that, as I mentioned, we'll be running a substantial direct-to-consumer campaign. And when I say consumer, I mean a caregiver; we'll make sure we're connecting with them and building brand awareness of ZORYVE for this population, so that caregiver knows it's out there. Then, regarding the approximate figure, it's roughly $2 million to $2.5 million in terms of the patients — the opportunity that exists in this age group with atopic dermatitis.

Todd Watanabe executive
#29

And Latha, can you address Uwe's question about the OpEx?

Latha Vairavan executive
#30

Yeah. For the first quarter, I'd characterize SG&A as just a bit under consensus, though we aren't seeing any kind of sharp drop. So there's no reason for worry on that front. The field force ought to have gotten underway during Q2. A piece of that will show up in Q2's actual results. So there's going to be some normalization there. When it comes to the primary care field force expansion, that's taking place in the back half of the year — that's what the remark about a modest increase is pointing to. And regarding a few of the initiatives Todd mentioned, you'll also see a portion of those costs unfold across the year. So that sums up where we stand on SG&A running higher than the prior year.

Serge Belanger analyst
#31

Starting with the first item, about ZORYVE coverage — should we anticipate any progress on the Medicaid and Medicare pieces that are still outstanding? Or does that fall more into 2027? I'm just wondering whether it might be possible to move it up into 2026. Then, on the sales force expansion, you'll be calling on prescribers in lower deciles. I'd like to know how those differ from the higher decile ones. Clearly, volumes come in smaller, but do they typically write fewer topical products compared with the higher decile prescribers?

Todd Watanabe executive
#32

Yes. Todd, apologies for putting you on the spot, but could — do you want to handle those 2?

Todd Edwards executive
#33

Absolutely, glad to take that. That's a terrific question, so thanks for it. The first part, on the coverage side and the progress we're making with Medicaid and Medicare: we'll keep gaining ground in Medicaid. We're able to do that during 2026 as we keep signing contracts with those individual states for fee-for-service Medicaid. Right now we're in negotiations and talks with a number of those states where ZORYVE isn't on formulary. On the Medicare side, that's a longer road. We have to sign contracts with every independent Part D plan. And usually, those formulary updates happen at the start of the year. So it's — I'd say it's probably going to be January 1, 2027, though there is a chance with the Part D plans to move that up into 2026. And as we've said before, ZORYVE has access in roughly 1/3 of the Part D plans. It's our goal to keep speeding that up going forward, and we'll do everything we can to move that up into 2026; and then the other piece concerns the sales force expansion — yes, you've got that right. What we're aiming for is a greater frequency, a deeper level of engagement with med decile providers, without spreading that frequency thinner among the higher decile providers. And the main thing that separates high decile from medium decile is the prescribing opportunity, meaning they have a bigger — the higher deciles have a bigger patient base, a bigger patient load. They also generally tend to adopt branded products faster; but with these median decile providers, there's plenty of opportunity for us to keep growing ZORYVE, and we believe that frequency will drive greater adoption of ZORYVE.

Rich Law analyst
#34

This is Tan, filling in for Rich. First, regarding the primary and pediatric care setting, I'm curious whether you could elaborate on how your approach there differs from CALA's. Which areas did they struggle in that you believe you can do better on? Then I have a follow-up.

Todd Edwards executive
#35

Yeah. No, that's a great question. Thank you. I apologize, Frank. I just cut in. Thank you. So the way our approach differs is — well, what — I wouldn't describe it as the way our approach differs so much as what we will do to ensure this primary care team is positioned for success and that we can drive utilization of ZORYVE within these specialties, which is that, as I mentioned, as we assemble this team at launch, our focus will be intense. We're examining, and we've managed to construct the target list, to ensure we'll be engaging the most opportunistic primary care and pediatricians. And by most opportunistic, I mean these will be the PCPMPs with the largest patient loads across the 3 indications for which ZORYVE is approved, and beyond that, these providers have shown a willingness to adopt branded products. And these will be located within the major metropolitan areas. Also, we'll ensure that across each of these representative territories, we'll have a set number of targets, so that representative can achieve the right frequency on every target to drive trial and adoption of ZORYVE. Again, positioning this for success. And as we achieve success, we'll keep scaling from there moving forward.

Analyst analyst
#36

All right, understood. And then regarding the second item — the foam for vitiligo as well as HS — which efficacy thresholds would you consider adequate for you to feel confident about moving forward with development in those 2 indications?

Todd Watanabe executive
#37

Certainly. Todd, your turn to respond. Patrick, would you like to handle that question?

Patrick Burnett executive
#38

Appreciate it. Sure. So when we consider vitiligo along with HS, we should remember these are trials that are smaller and open-label — the core question we're chasing is how the ZORYVE profile stacks up against what's currently used as standard of care; therefore in vitiligo, we're essentially examining how quickly responses come about compared with Opzelura. It's well known that a major difficulty for vitiligo patients is the speed at which they notice skin improvement, since that factor strongly influences whether they stick with treatment. So after a patient begins therapy, should the results they're hoping for not appear, there are times when they'll abandon treatment; and that, I believe, is precisely where ZORYVE's mechanism comes in, with PDE4 acting on the inflammatory side, plus, as we described before, we've observed some signs — our hypothesis — of a possible effect on melanocyte protection itself and on pigment generation. That's our reasoning for why a faster response rate could emerge. So we're assessing what that profile amounts to; then, turning to HS, or hidradenitis suppurativa, something we genuinely hope to determine is how we shift these patients during earlier stages of the disease and, since no truly effective topical is currently in use for HS patients, how this treatment would slot into the treatment paradigm that's taken shape, in which a great many of those patients get moved onto systemics fairly rapidly even when their disease might be controllable through a good topical. So in that instance, I'd say we perceive somewhat more blue sky. And what we intend to lay out once we reach Q4 for vitiligo is a fairly clear picture of what the response profile is showing us, along with where the commercial opportunity lies and how that profile would fit within the landscape.

Todd Watanabe executive
#39

Yes. Perhaps I can offer one more point to what Patrick said. I believe particularly when it comes to HS — and we observed this once more in today’s APOLLO data — systemic treatments don’t work especially well for this condition, so even people receiving systemic therapy frequently will still require add-on care. And ZORYVE stands out in a truly distinctive way among topicals, since it can be used safely alongside systemic therapies. The disease also tends to appear in intertriginous regions, the increasing underarm areas, where physicians are far more hesitant to prescribe topical steroids too. So I think for early-stage disease, and likewise as an add-on to systemic therapy, as we’re seeing with psoriasis and atopic dermatitis, ZORYVE has a uniquely persuasive profile for that use case as well.

Todd Watanabe executive
#40

All right, then. Once more, I want to express my gratitude to each of you for setting aside the time. I realize this period of the year keeps all of you quite occupied, so I'm grateful that you joined the call, and I'm eager to speak with everybody again when the next quarter comes around. Thank you. Goodbye.

Operator operator
#41

We appreciate everyone joining us for this call today. That brings the program to a close. You're free to leave the line now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arcutis Biotherapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Arcutis Biotherapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.